Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Adjuvant dabrafenib plus trametinib bij stadium III-melanoom: 10 jaar follow-up
aug 2024 | Dermato-oncologie